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To determine the patterns of chest computed tomography (CT) evolution according to disease 
severity in a large coronavirus disease 2019 (COVID-19) cohort in Jiangsu province, China. 
Methods 
This retrospective cohort study was conducted from January 10, 2020 to February 18, 2020. All 
patients diagnosed with COVID-19 in Jiangsu province were included, retrospectively. 
Quantitative CT measurements of pulmonary opacities including volume, density and location 
were extracted by deep learning algorithm. Dynamic evolution of these measurements was 
investigated from symptom onset (day 1) to beyond day 15. Comparison was made between 
severity groups. 
Results 
A total of 484 patients (median age of 47 years, interquartile range: 33-57) with 954 CT 
examinations were included and each was assigned to one of three groups: asymptomatic/mild 
(n=63), moderate (n=378), severe/critically ill (n=43). Time series showed different evolution 
patterns of CT measurements in the groups. Following disease onset, posteroinferior subpleural 
area of the lung was the most common location for pulmonary opacities. Opacity volume 
continued to increase beyond 15 days in the severe/critically ill group, compared to peaking on 
day 13-15 in the moderate group. Asymptomatic/mild group had the lowest opacity volume which 
almost resolved after 15 days. The opacity density began to drop from day 10-12 for moderate ill 
patients. 
Conclusions 
Volume, density and location of the pulmonary opacity and their evolution on CT varied with 
disease severity in COVID-19. These findings are valuable in understanding the nature of the 
disease and monitoring the patient’s condition during the course of illness. 
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1. Coronavirus;  
2. Multidetector computed tomography;  




1) Volume, density and location of the pulmonary opacity on CT change over time in 
COVID-19. 
2) The evolution of CT appearance follows specific pattern, varying with disease severity. 
 
Abbreviations: 
AI = artificial intelligence 
CI = confidence interval 
COVID-19 = coronavirus disease 2019 
CT = computed tomography 
GGO = ground glass opacity 
ICU = intensive care unit 
IQR = interquartile range 
SaO2 = arterial oxygen saturation 
SD = standard deviation 




































































At the end of 2019, an outbreak of a highly contagious viral pneumonia was reported in Wuhan, 
China and the causative agent was confirmed to be a novel coronavirus, termed as COVID-19 by 
World Health Organization [1]. The disease spread to all provinces in China and many countries 
overseas, leaving more than 400 thousand people infected as of March 25, 2020 [2][3]. Jiangsu 
province has the fifth largest population in China and has reported more than 600 infected cases 
[4].  
Computed tomography (CT) examination plays an important role in the evaluation of COVID-19. 
According to the 5th edition of diagnosis and treatment standards for novel coronavirus 
pneumonia published by the Chinese National Health Commission, CT examination is one of the 
three main diagnostic criteria. In Hubei province the clinical diagnosis of COVID-19 comprises of 
only clinical and radiological proof, irrespective of the nucleic acid test result, thus highlighting 
the importance of CT imaging assessment [5].  
Some typical radiological findings including subpleural ground-glass opacities (GGO) and 
consolidation have been reported as well as the dynamic evolution of these lesions [6–10]. 
However, these measurements were mainly based on visual evaluation, which are subjective and 
inaccurate. In addition, imaging evolution according to disease severity has rarely been reported, 
which we believe is critical for understanding the nature of the disease and monitoring disease 
change in a stratified manner.  
In this retrospective study, quantitative assessment of imaging characteristics and dynamic 
evolution was evaluated. Comparison was made among patients with variable disease severity. 
 
Materials and Methods 
This study was approved by the ethics committee of Zhongda hospital (2020ZDSYLL013-P01 and 
2020ZDSYLL019-P01) and informed consent was waived due to the emergent event of the 
pandemic. 
Clinical information and imaging data for all COVID-19 patients diagnosed in Jiangsu before Feb 
18, 2020 were obtained, retrospectively from electronic medical records, established by the 
Department of Health, Jiangsu province.  



































































were excluded. Figure 1 shows the detailed flow chart of this study. 
Based on the 5th edition of the guideline for diagnosis and treatment of COVID-19, published by 
National Health Commission of the People’s Republic of China on February 8, 2020, patients 
were assigned into three groups, classified according to disease severity; asymptomatic/mild, 
moderate, or severe/critically ill. Patients were classified as (i) “asymptomatic” if they had no 
symptoms of disease, (ii) “mild” if they had mild clinical symptoms, but no imaging abnormality, 
(iii) “moderate” if they had one or more symptoms (fever, cough, diarrhea, etc.) and imaging 
showed manifestations of pneumonia or (iv) “severe” if they had one of the following conditions: 
a) respiratory distress presenting with respiratory rate ≥ 30 beats/min, b) mean oxygen saturation 
in resting state ≤ 93%, c) arterial blood oxygen partial pressure/oxygen concentration ≤ 300 
mmHg. (v) Patients with either shock, respiratory failure requiring mechanical ventilation, or 
combined organ failure requiring admission to an intensive care unit (ICU) were classified as 
“critically ill”.  
In order to analyze the evolution of imaging and clinical characteristics, the day when the initial 
symptoms emerged was defined as day 1. When no initial symptoms were reported, the date of 
outpatient visit was used as day 1. The time points for each CT scan, change of severity grading 
relative to day 1 were recorded and were further assigned to day 1-3, day 4-6, day 7-9, day 10-12, 
day 13-15 and beyond day 15. 
 
CT acquisition  
CT imaging was performed using multi-slicer CT scanners. Thin section images were collected 
preferentially. For further details relating to the acquisition of CT images please see Table S1. All 
raw data with format of Digital Imaging and Communications in Medicine were then transferred 
to work stations for post-processing.  
 
Imaging analysis 
Lung segmentation, lesion extraction and labeling were performed using a dedicated artificial 
intelligence (AI) system with deep learning algorithm for pulmonary pneumonia (Deepwise & 
League of PhD Technology Co.Ltd). The AI algorithm achieved a dice of 0.97 in the HOUSE 



































































the AI system in lesion extraction and labeling was also manually checked by an investigator 
(Y.W.) with more than 10 years of experience in chest imaging. Bilateral lungs were segmented 
into right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe 
automatically, and extraction of pulmonary opacities was carried out at the same time. All 
extracted opacity pieces were annotated as GGO or consolidation by the AI system and were 
approved by an investigator (Y.W.). The masks of opacities and each lung’s lobes were saved for 
further voxel-based measurements including volume, X-ray attenuation and location. Detailed 
information regarding segmentation and lesion extraction are available in supplemental methods.  
Further assessment of segmented lobes and extracted opacities was performed as follows: 
1) Volume measurement: included volume of bilateral lungs, GGO, consolidation, GGO + 
consolidation, and aerated lung.  
2) Density measurement: included the X-ray attenuation of bilateral lungs, overall opacities, 
opacities in upper lobes including bilateral upper lobes and right middle lobe and opacities in 
bilateral lower lobes.  
3) Location analysis: A standard lung was selected from a healthy 37-year male without lung 
abnormalities. Subsequent registration and projection of all included chest CT images to the 
standard lung was performed. Voxel-based frequencies of opacity were measured by drawing 
five volumes of interest (VOIs) in the standard lung, with each of the VOI larger than 15 mL. 
Four VOIs were placed in the subpleural areas (within 15 mm from the pleura), which were 
right posteroinferior subpleural area, right posterosuperior subpleural area, right anterior 
subpleural area, right medial subpleural area, and the last one was placed in the right central 
area 20 mm away from the pleura (Figure S1). The number of lobes with pulmonary opacities 
was also recorded, and scored from 0 to 5, with 5 indicating all 5 lobes were involved. 
4) Dynamic evolution: Dynamic change of volume, density, and frequency of opacities by 
location from symptom onset (day 1) to beyond day 15 were investigated.  
 
Clinical and laboratory characteristics 
Demographic information, exposure type, initial symptoms (fever, cough, sputum, shortness of 
breath, dyspnea, anorexia or diarrhea), possible exposure time, time of initial symptoms, date of 



































































saturation (SaO2), blood cell counts (blood leukocyte count, lymphocyte count, and platelet count) 
and biomarkers of inflammation (C-reactive protein level, procalcitonin level, lactate 
dehydrogenase), hepatic and renal function (aspartate aminotransferase level, alanine 
aminotransferase level, creatinine level), and coagulation (D-dimer level) were collected. 
 
Statistical analysis 
All consecutive data were listed as means ± standard deviations (SDs) or medians with 
interquartile ranges (IQRs) for Gaussian and skewed distributed data. Skewed distributed data 
were tried to converted to Gaussian distribution by logarithmic transformation for variance 
analysis. Chi-square test, Kruskal-Wallis or Mann-Whitney test were used to examine statistical 
differences for ratio and skewed distributed data. All statistical analyses were performed using R 




A total of 626 patients diagnosed with COVID-19 from 24 designated hospitals in Jiangsu 
province were initially recruited to this study. One hundred and forty-two patients were excluded 
from the study because of either no clinical records or missing or incomplete chest CT images, or 
images with poor quality (Figure 1). The remaining 484 patients from 21 hospitals (3 were 
excluded) were assigned to three severity groups (asymptomatic/mild, n=63; moderate, n=378; 
severe/critically ill, n=43). Baseline characteristics were shown in Table 1. There was marked 
disparity in median age between the three groups, manifesting as an increased age with increased 
severity (p < .001). Fever (up to 83.7%) and cough/sputum (up to 69.8%) were the most common 
symptoms in symptomatic patients. Analyses of laboratory test results for SaO2, blood leukocyte 
count, lymphocyte count, platelet count showed downward trends from asymptomatic/mild to 
severe/critically ill. Conversely, C-reactive protein, lactate dehydrogenase, aspartate 
aminotransferase and D-dimer concentrations above the normal range (≥ 10 mg/L, ≥ 250 U/L, > 
40 U/L and ≥ 0.5 mg/L, respectively) tended to be more common in patients with severe disease. 
Patients with severe disease tended to have more adverse events including admission to ICU, 



































































membrane oxygenation (34.9%, p < .001). 
 
Imaging characteristics by severity 
A total of 954 CT scans were performed in the 484 patients (asymptomatic/mild 122 [12.8%], 
moderate 747 [78.3%], severe/critically ill 85 [8.9%]). Number of CT scans by disease severity 
and time points were illustrated in Figure S2. The imaging characteristics are shown in Table 2. 
Among the asymptomatic/mild group, 14.8% of CT scans showed no abnormal findings, and this 
was significantly greater than for the other two groups (p < .001). When pooling CT scans at 
different time points together, volume, density and location demonstrated significant differences 
between the three groups. The severe/critically ill group showed the lowest total lung volume and 
aerated lung and greatest volume of pulmonary opacities with 3548.7 mL, 2557.0 mL and 491.4 
mL, respectively. For different components and locations of opacities, volume of consolidation 
was more than GGO and volume of opacities in the lower lungs were more than that in the upper 
lungs. Declines were found in attenuation as disease severity decreased. 
Heterogenous distribution of the pulmonary opacities was observed in all groups. The most 
common location for opacities was the subpleural area of posteroinferior lung (Figure S3), most 
prominently in the severe/critically ill group with frequency of 45.3%, followed by the subpleural 
area of posterosuperior lung (32.6%), the other areas (anterior and medial subpleural areas, central 
area) were comparable with frequencies of 22.1% to 26.7%. The frequencies dropped with 
decreased disease severity, in all locations of the lung (Table 2, Figure 2). 
In patients in the severe/critically ill group, significantly more lung lobes were involved compared 
to the other two groups, with median number of lobes of 5 (5 to 5), 5 (3 to 5) and 3 (1 to 4), 
respectively, P < .001. 
 
Dynamic evolution of imaging characteristics 
The three groups showed different progressive and regressive imaging patterns (see supplemental 
video). 
The opacity volume was the greatest in the severe/critically ill group during the whole study 
period (Figure 3A). Time series showed that opacity volumes (mainly for consolidation) continued 



































































However, for the moderate group, opacity volume maintained a steady state after day 13-15, 
account of 7.7% of the whole lung. In the asymptomatic/mild group, the highest opacity volume 
was on day 1-3 (mean: 1.9%, 95% confidence intervals [CI]: 3.2%), which dropped gradually to 
the lowest level beyond day 15 (mean: 0.9%, 95% CI: 0.3%) (Figure 3B). When classifying the 
opacities into GGO and consolidation, a remarkable decrease trend of GGO was observed 
compared to increase trend of consolidation in the severe/critically ill group.  
 
In the moderate group, the attenuation showed a trend of increase in the initial 9 days after 
symptom onset, and decrease after day 12. Overall median attenuation in the severe/critically ill 
group was significantly higher than in the moderate group (-576 HU vs -634 HU, p = 0.002). 
Opacities in the lower lobes had higher attenuation than that in the upper lobes (-534 HU vs -634 
HU for the severe/critically ill group, -624 HU vs -676 HU for the moderate group, p<.001). An 
increase trend of attenuation was perceived beyond day 15 in the severe/critically ill group, 
compared to continuous decline in the moderate group (Figure 3C, Figure 4). 
Change of opacity frequency by day synchronized with the volume, most evidently in the 
posteroinferior subplerual area, reaching 61.6% in severe/critically ill group, verses 25.1% and 
5.5% in the moderate and the asymptomatic/mild group, respectively (Figure 3D).  
 
Discussion 
In this province-based multicentre study, we have described CT imaging patterns and dynamic 
evolution in patients with COVID-19, according to disease severity. Jiangsu, an eastern Chinese 
province, with an area of 40,000 square miles and a population of about 80 million (ranked fifth in 
China provinces) is a representative district, and our findings may be of relevance to many other 
countries. The low death toll (no deaths in this study) and high proportion of patients with 
moderate disease severity due to COVID-19 observed in our study are similar to reports from 
many other countries [2], and may indicate the common nature of COVID-19. 
 
The demographics and clinical/laboratory findings in our study are also comparable to previously 
reported data [3, 8, 11]. Severe cases tended to be older, had a shorter incubation period, had more 



































































and experienced more serious adverse events. The early CT findings (3 days after onset) in this 
study were characterized as predominately subpleural GGO and posterior basal predominance for 
patients with different disease severity, consistent with previous studies [6, 12].  
 
There was a tendency of subpleural distribution for pulmonary opacities, consistent with the 
underlying pathogenic pattern that distal bronchioles as well as alveolar epithelial cells impaired 
in viral pneumonia [13, 14]. The posterior basal predominance shown in the heat map may due to 
the predilection of atelectasis posteriorly, corresponding to heterogeneous pulmonary opacity 
distribution in patients with acute respiratory distress syndrome [15]. Among all subpleural areas, 
the posteroinferior area of the lung showed leading frequency of opacity distribution as indicated 
in Figure 3D, which may due to the anatomical characteristics of the bronchus: more vertical for 
lower lobes compared with the other lobes. This makes the lower lobes more susceptible to 
pathogen attack [8]. Our study further demonstrated a discrepancy in subpleural distribution which 
has not been elaborated in previous studies: the medial and anterior subpleural areas were less 
frequently involved compared to the posterior subpleural areas.   
 
Part of the pulmonary opacities presented as GGO in this study, especially in the early stages of 
disease. This finding is consistent with several studies [8, 10, 16–18]. Although our understanding 
of the pathological mechanisms and effects of this specific novel coronavirus are limited, there is 
some evidence to explain the underlying causes of these radiological manifestations. In a study of 
two patients with lung adenocarcinoma surgery superimposed with COVID-19, damage of alveoli 
together with proteinaceous and fibrous exudation, accounted for the early appearance of GGO on 
chest CT [19]. In studies of severe acute respiratory syndrome (SARS), focal lung injury was 
related to early radiologic findings [20]. As SARS and COVID-19 are both caused by coronavirus, 
it is possible that some of their pathological process overlap [21]. As the disease progresses, more 
inflammatory cells infiltrate the alveoli and interstitial space, followed by diffuse alveolar damage 





































































As for the dynamic evolution, a study of 63 COVID-19 patients from Wuhan showed an increased 
range of GGO and consolidation in 3-14 days after onset of symptoms [17]. Pan et al. identified a 
peak stage of 9-13 days for lung involvement after symptom onset in 21 patients [10], compared 
to 6-11 days from another study of 90 patients [9]. In our study, we used an AI algorithm to 
automatically and quantitatively measure the percentage of opacity volume in 484 patients, which 
is different from scoring system based on visual evaluation in previous studies [9, 10, 17]. We 
concluded a peak stage of 13-15 days for opacity volume after symptom onset in moderately ill 
patients – the large majority in this study. Notably, for severe/critically ill patients, this peak stage 
extended to beyond 15 days, while for mild/asymptomatic patients, the peak stage was just at the 
first 3 day after symptom onset. In severe/critically ill patients, different evolution patterns for 
GGO and consolidation were observed. There was a trend that GGO reduced continuously along 
with consolidation aggregation, suggesting a transformation of GGO to consolidation, during the 
course of disease. Varied patterns of imaging evolution are particularly useful in dynamically 
evaluating disease severity. 
AI has been developed fast in recent years, and has already been used to distinguish pneumonia in 
COVID-19 from community acquired pneumonia [23]. The preliminary results are promising, but 
it should be noted the pre-test probability of COVID-19 varied with cities as well as countries, the 
positive predictive value of CT, even combined with AI, may low in areas with low pre-test 
probability [24]. It should be avoided to overstate the role of AI in the diagnosis of COVID-19. In 
this study, however, we did not use AI to diagnose COVID-19, but for pulmonary lobe 
segmentation, lesion extraction and GGO / consolidation labeling, these techniques are relatively 
mature. And the accuracy was verified in the study. 
Our retrospective study has several limitations. Firstly, prospective studies of CT examination and 
patterns of evolution should be undertaken and validated in more institutions. Secondly, the 
relatively small sample size of mild/asymptomatic cases resulted in relatively large variation in 
certain measurements. Consequently, although trends for some changes were observed, they did 
not reach statistical significance. Therefore, further studies that include more patients with 
asymptomatic/mild disease cases are required to strengthen the statistical power. Thirdly, opacity 
changes on CT were still progressing in the severe/critically ill patient group at the end of the 



































































period to determine the potential break point for these patients. Finally, since CT findings were 
significantly different between the severity groups, we hypothesize that a combined CT score 
could be developed to classify disease severity, and predict disease outcome at an early stage. We 
plan to undertake this work in the near future. 
 
Conclusion 
In this multicentre study of patients with COVID-19, we have shown that pulmonary opacities 
vary in volume, density and location, as well as the dynamic evolution, according to disease 
severity. Our findings provide insight into the nature of the disease and are potentially valuable in 
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Table 1 Baseline characteristics of study patients. 
Table 2. Computed tomography (CT) results in patients with COVID-19, according to disease 
severity 
Figure 1. Flowchart of the study 
Figure 2. Three-dimensional heat maps show the frequency of location of pulmonary opacities in 
COVID-19 from the onset of symptoms (day 1) to beyond day 15. Asymptomatic/mild patients 
have trace opacities, resolving partially after 15 days (top row). Moderately ill patients have more 
opacities and peaked on day 13-15, predominantly located in the posteroinferior subpleural area 
(middle row). Severe/critically ill patients have the most prominent opacities and continue to 
progress beyond day 15 (bottom row). Axial frequency map shows typical pattern of posterior 
subpleural distribution of the opacities with decreased frequency in the anterior and medial 
subpleural areas.  
 
Figure 3. CT measurements changing by day (A-D). (A) In the severe/critically ill group, volume 
of aerated lung decreased while pulmonary opacities increased by day. (B) Volume of 
consolidation kept growing beyond 15 days in the severe/critically ill group, while peaked on day 
13-15 in the moderate group. (C) The density of opacities dropped after day 12 in the moderate 
group; opacities in lower lobes had higher attenuation than that in upper lobes. (D) Posteroinferior 
subpleural area was the most common involved location in the lung, and the variation trend was 
similar to volume change in figure B.  
 
Figure 4. A 64-year old male diagnosed with moderate COVID-19. Non-contrast chest CT were 
performed on day 5, 8, 10, 15 after the onset of initial symptoms (A-D). The pulmonary opacities 
kept similar volume while the density decreased heterogeneously on day 15 compared to day 10. 
 
Figure 5. A 56-year old female diagnosed with severe COVID-19. Non-contrast chest CT were 
performed on day 5, 11, 14, 17 after the onset of initial symptoms (A-D). The bilateral subplueral   







































































(n= 63, 13.0%) 
Moderate 
(n= 378, 78.1%) 
Sever/critically ill 
(n= 43, 8.9%) 
p value 
Age, years 33 (22, 51) 46 (34, 56) 59 (52, 71) <.001 
Gender, male 31/63 (49.2%) 202/378 (53.4%) 27/43 (62.8%) 0.377 
Incubation period, days 8 (5, 11) 6 (3, 10) 5 (3, 8) 0.125 
Initial symptoms     
  Fever 14/30 (46.7%)c 278/378 (73.5%) 36/43 (83.7%) <.001 
  Cough/sputum 19/30 (63.3%)c 224/378 (59.3%) 30/43 (69.8%) <.001 
  Shortness of breath/Dyspnea 0/30 (0%)c 10/378 (2.7%) 5/43 (11.6%) 0.007 
Comorbiditya  8/63 (12.7%) 76/378 (20.1%) 16/43 (37.2%) 0.008 
Exposure type     
  Wuhan exposure 18/63 (28.6%) 148/378 (39.2%) 16/43 (37.2%) 0.275 
  COVID-19 patients exposure 34/63 (54.0%) 139/378 (36.8%) 12/43 (27.9%) 0.012 
  Contact historyb 8/63 (12.7%) 40/378 (10.6%) 8/43 (18.6%) 0.284 
  No exposure 3/63 (4.8%) 51/378 (13.5%) 7/43 (16.3%) 0.116 
Type of disease     
  Single onset 10/63 (15.9%) 199/378 (52.6%) 23/43 (53.5%) <.001 
  Clustering onset 53/63 (84.1%) 179/378 (47.4%) 20/43 (46.5%) <.001 
Laboratory tests     
  SaO2, % 98.2 (98.0, 98.4) 97.9 (96.4, 99.0) 95.3 (93.2, 97.3) <.001 
  Blood leukocyte count, *10^9/L 5.3 (4.5, 6.6) 4.8 (3.8, 6.0) 4.2 (3.5, 5.9) 0.033 
        <4*10^9/L 9/57 (15.8%) 93/309 (30.1%) 14/37 (37.8%) 0.040 
        >10*10^9/L 1/57 (1.8%) 5/309 (1.6%) 3/37 (8.1%) 0.077 
  Lymphocyte count, *10^9/L 1.8 (1.3, 2.5) 1.3 (1.0, 1.7) 0.6 (0.5, 0.9) <.001 
        <1.5*10^9/L 18/54 (33.3%) 195/318 (61.3%) 36/37 (97.3%) <.001 
Platelet count, *10^9/L 216 (164, 263) 182 (152, 212) 154 (120, 191) <.001 
        <150*10^9/L 9/58 (15.5%) 71/322 (22.0%) 15/37 (40.5%) 0.014 
Table
 2 
  C-reactive protein, 10mg/L 4/50 (8.0%) 143/300 (47.7%) 19/31 (61.3%) <.001 
  Procalcitonin, 0.5ng/mL 5/50 (10.0%) 55/295 (18.6%) 6/27 (22.2%) 0.274 
  Lactate dehydrogenase, 250U/L 6/37 (16.2%) 103/232 (44.4%) 17/26 (65.4%) <.001 
  Aspartate aminotransferase, >40 U/L 4/48 (8.3%) 71/270 (26.3%) 13/30 (43.3%) 0.002 
  Alanine aminotransferase, >40U/L 6/46 (13%) 70/273 (25.6%) 8/30 (26.7%) 0.170 
  D-dimer, 0.5mg/L 11/54 (20.4%) 75/311 (24.1%) 17/36 (47.2%) 0.007 
  Creatine, umol/L 63 (47, 79) 63 (50, 78) 62 (51, 82) 0.975 
ICU /IMV/CRRT/ECMO 1/63 (1.6%) 13/378 (3.4%) 15/43 (34.9%) <.001 
Categorical variables are expressed as number (percentage) while continuous variables are described as median and interquartile range. 
a: Comorbidity include hypertension, coronary heart disease, cardiac dysfunction - , poor physical fitness (unable to climb stairs, do daily 
housework, etc.), gastrointestinal hemorrhage caused by cirrhosis, hepatic encephalopathy and portal hypertension, diabetes, chronic kidney 
dysfunction, dialysis, malignant tumor, hematological malignancies, connective tissue disease, stroke. 
b: Contact history refers to those patients who had contact with people from Wuhan before the onset of disease. 
c: A total of 33 patients were asymptomatic in the asymptomatic/mild group and were excluded when calculating the symptom percentage. 
ICU: intensive care unit, IMV: Invasive Mechanical Ventilation, CRRT: Continuous Renal Replacement Therapy, ECMO: Extracorporeal 
Membrane Oxygenation. 
 





(n =63, 13.0%) 
Moderate 
(n= 378, 78.1%) 
Severe/critically ill 
(n= 43, 8.9%) 
P value 
Number of chest CT examinations 122/954 (12.8%) 747/954 (78.3%) 85/954 (8.9%) - 
Number of CT examinations without 
pulmonary opacity 
18/122 (14.8%) 15/747 (2.0%) 0/85 (0%) <.001 
Number of CT examinations with slice 
thickness ≤ 3 mm 
114/122 (93.4%) 654/747 (87.6%) 72/85 (84.7%) 0.108 








4216.6 (3307.1, 5094.7) 2557.0 (1921.0, 3921.7) <.001 
Pulmonary opacities 1.7 (0.1, 44.9) 129.8 (34.0, 302.5) 491.4 (199.0, 1041.0) <.001 
Ground glass opacities 0.1 (0, 5.7) 9.1 (1.2, 32.5) 14.8 (0.9, 66.4) <.001 
Consolidation 0.4 (0, 20.3) 97.5 (16.8, 238.8) 437.3 (134.2, 977.8) <.001 
Opacities in the upper lobes 0 (0, 1.8) 22 (0.7, 98.7) 227.7 (46.6, 496.2) <.001 
Opacities in the lower lobes 0 (0, 28.7) 76.2 (13.8, 190.1) 288.3 (102.4, 554.6) <.001 
Density (X-ray attenuation, Hu)     
Whole lung -847 (-864, -821) -826 (-856, -786) -750 (-802, -684) <.001 
Pulmonary opacities -602.5 (-713, -484) -634 (-711, -540) -576 (-666, -523) 0.003 
Opacities in the upper lobes -656 (-736, -566) -676 (-744, -577) -634 (-696, -560) 0.009 
Opacities in the lower lobes -586 (-689, -479) -624 (-708, -518) -534 (-645, -443) <.001 
Frequencies of opacity by location (%)     
Right posteroinferior subplerual area 4.7 (2.4, 7.1) 20.5 (18.6, 22.6) 45.3 (43.0, 48.8) <.001 
Right posterosuperior subplerual area 1.6 (0.8, 1.6) 10.8 (8.5, 12.6) 32.6 (29.1, 34.9) <.001 
Right anterior subplerual area 1.6 (1.6, 3.1) 5.3 (4.4, 6.6) 24.4 (20.9, 26.7) <.001 
Right medial subplerual area 1.6 (1.6, 1.6) 4.1 (3.5, 5.2) 22.1 (19.8, 26.7) <.001 
Right central area 1.6 (0.8, 1.6) 4.9 (4.5, 5.5) 26.7 (23.3, 27.9) <.001 
Lung lobes involved 3 (1, 4) 5 (3, 5) 5 (5, 5) <.001 
 4 
 
Variables are described as number (percentage) or median and interquartile range. 
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